A Phase 1, Open-Label Study, to Evaluate the Safety and Tolerability of multiple inhalation of SM04646 Inhalation Solution in Subjects with Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 24 Feb 2022
At a glance
- Drugs SM 04646 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Biosplice Therapeutics; Samumed
- 27 May 2019 Status changed from recruiting to completed.
- 23 Jan 2019 Anticipated date last participant enrollment is 3/30/2019. Also, the accrual to date is 8.
- 18 Jan 2019 Planned End Date changed from 30 Dec 2018 to 31 May 2019.